百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

午间休市 05-07 12:44:24

142.200

-11.000

-7.18%

最高149.300	最低141.700	成交量649.66万
今开148.300	昨收153.200	日振幅4.96%
总市值1,995亿	流通市值1,832亿	总股本14.03亿
成交额9.39亿	换手率0.50%	流通股本12.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":142.2,"timestamp":1746593064577,"preClose":153.2,"halted":0,"volume":6496625,"delay":0,"floatShares":1288000000,"shares":1403000000,"eps":-3.6529851035616527,"marketStatus":"午间休市","change":-11,"latestTime":"05-07 12:44:24","open":148.3,"high":149.3,"low":141.7,"amount":938799855,"amplitude":0.049608,"askPrice":142.2,"askSize":800,"bidPrice":141.9,"bidSize":3700,"shortable":3,"etf":0,"ttmEps":-3.6529851035616527,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746594000000},"marketStatusCode":3,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":153.2,"openAndCloseTimeList":[[1746581400000,1746590400000],[1746594000000,1746604800000]],"volumeRatio":2.967833,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":240.07,"timestamp":1746588597000,"preClose":259,"halted":0,"volume":2797500,"delay":0,"premium":"-44.83"}},"requestUrl":"/m/hq/s/06160/tweets","defaultTab":"tweets","newsList":[{"id":"2533506576","title":"百济神州总裁吴晓滨：将医疗信息进行整合并发现规律，可为人类健康带来巨大福祉","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506576","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533506576?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:20","pubTimestamp":1746523200,"startTime":"0","endTime":"0","summary":"　　4月21日，2025年中国绿公司年会聚焦“医疗健康与生命科学”主题举办高级别闭门研讨。百济神州总裁、首席运营官吴晓滨作题为《创新药的发展与思考》的演讲。　　吴晓滨说，当今无论是发达国家还是发展中国家，有约 80% 的国家所面临的医疗状况与我国十几年前相似——进口药品价格高昂。如果能够整合并结构化处理这些数据，其中蕴含着大量未被发现的生命奥秘和疾病治疗规律，将会对中国人民乃至全人类的健康带来巨大的福祉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2025-05-06/doc-inevrkva2208050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","BK1161","688235","02197","ONC","159891","BK4139","LU2328871848.SGD","06160","BK1583","LU0307460666.USD","LU0588546209.SGD","BK1500","BK1588","BK0239"],"gpt_icon":0},{"id":"2533536538","title":"东吴证券：给予百济神州买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2533536538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533536538?lang=zh_cn&edition=full","pubTime":"2025-05-05 22:50","pubTimestamp":1746456641,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对百济神州进行研究并发布了研究报告《2024年年报点评：营收大幅增长，2025年将迎来 GAAP经营性利润转正》，给予百济神州买入评级。公司作为国内创新药龙头，临床开发效率卓越，全球商业化能力突出，成长确定性较高，财务报表端即将扭亏，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为271.06。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050500003298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","601555","688235"],"gpt_icon":0},{"id":"2532397845","title":"累亏超600亿元！市值却超3600亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532397845","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532397845?lang=zh_cn&edition=full","pubTime":"2025-05-04 13:59","pubTimestamp":1746338381,"startTime":"0","endTime":"0","summary":"百济神州4月28日晚发布的2024年年报显示，2024年公司亏损49.78亿元，是2024年亏损金额最多的医药上市公司；累计未弥补亏损为626.67亿元。2024年，恒瑞医药实现营业收入279.85亿元，同比增长22.63%；归属于上市公司股东的净利润为63.37亿元，同比增长47.28%。2024年，百利天恒营业收入为58.23亿元、同比增长936.31%；净利润达37.08亿元，同比增长575.02%；毛利率达95.46%，超过贵州茅台的91.93%。文章来源：中国基金报累亏超600亿元！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK4139"],"gpt_icon":0},{"id":"2532360144","title":"百济神州胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2532360144","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532360144?lang=zh_cn&edition=full","pubTime":"2025-05-04 10:01","pubTimestamp":1746324060,"startTime":"0","endTime":"0","summary":"百济神州宣布胜诉，USPTO裁定Pharmacyclics的‘803专利无效，该专利是艾伯维子公司对百济神州产品百悦泽®提出的侵权指控的核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","ONC","BK0239"],"gpt_icon":0},{"id":"2532185122","title":"港股医药股走势疲软，百济神州跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532185122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532185122?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:55","pubTimestamp":1746150915,"startTime":"0","endTime":"0","summary":"港股医药股走势疲软，百济神州跌近6%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505023395436693.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505023395436693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1500","LU0307460666.USD","BK1588","BK1583","LU2328871848.SGD","06160","LU0588546209.SGD","LU1969619763.USD","ONC","BK4139"],"gpt_icon":0},{"id":"2532633888","title":"两大千亿营收巨头领跑！云南白药首破400亿，百济神州、恒瑞大涨，人福、片仔癀……创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2532633888","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532633888?lang=zh_cn&edition=full","pubTime":"2025-05-02 08:09","pubTimestamp":1746144552,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502114021a46f932b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","ONC","600436","688235","000538","06160"],"gpt_icon":0},{"id":"2532071837","title":"百济神州因受限制股份单位获归属发行28.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071837","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532071837?lang=zh_cn&edition=full","pubTime":"2025-05-02 07:59","pubTimestamp":1746143940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属（公司董事除外）而发行28.8万股。\n　　于2025年4月30日，因合资格参与者（公司董事除外）行使购股权而发行合计113.1万股。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-02/doc-inevcpfk0018566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","BK4139","LU0588546209.SGD","688235","LU2328871848.SGD","BK1500","06160","BK1161","LU0307460666.USD","LU1969619763.USD","ONC","BK1583","BK0239"],"gpt_icon":0},{"id":"2532377318","title":"百济神州(06160)因受限制股份单位获归属发行28.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532377318","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532377318?lang=zh_cn&edition=full","pubTime":"2025-05-02 07:49","pubTimestamp":1746143373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年4月30日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行28.8万股。于2025年4月30日，因合资格参与者(公司董事除外)行使购股权而发行合计113.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","06160","LU0307460666.USD","LU0588546209.SGD","ONC","BK0239","BK1588","BK1583","LU1969619763.USD","BK4139","BK1161","LU2328871848.SGD","688235"],"gpt_icon":0},{"id":"2532704819","title":"跨国药企碰瓷失败，百济神州专利保卫战大捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2532704819","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532704819?lang=zh_cn&edition=full","pubTime":"2025-05-01 07:30","pubTimestamp":1746055845,"startTime":"0","endTime":"0","summary":"2025年4月29日，美国专利商标局作出了一项最终书面决定，宣布艾伯维旗下的Pharmacyclics公司在803专利授权后复审程序中受到质疑的803专利的全部权利无效。在2023年6月13日，Pharmacyclics公司作为申诉方，在美国特拉华州地方法院，对百济神州及其全资子公司BeOne Medicines USA提出申诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501104311a6cf956b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","ONC","BK0239"],"gpt_icon":0},{"id":"2532101739","title":"百济神州参投，可编程 mRNA实现 IL-12瘤内定向激活，开启“mRNA 2.0”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532101739","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532101739?lang=zh_cn&edition=full","pubTime":"2025-05-01 07:21","pubTimestamp":1746055260,"startTime":"0","endTime":"0","summary":"Strand Therapeutics展示了一种可编程mRNA疗法STX-003，能精准调控IL-12在肿瘤组织的表达，提高耐受性并维持抗肿瘤疗效，其核心优势在于自复制mRNA与遗传电路的结合，为肿瘤治疗提供创新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","ONC","BK1500","BK1161","BK1588","LU0588546209.SGD","LU2328871848.SGD","BK1583","LU1969619763.USD","06160","688235"],"gpt_icon":0},{"id":"2531205560","title":"美股异动 | 百济神州(ONC.US)涨逾3% 2024年收入同比增长55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531205560","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531205560?lang=zh_cn&edition=full","pubTime":"2025-04-30 21:59","pubTimestamp":1746021564,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报259美元。财报显示，百济神州2024年实现收入合计约38.1亿美元，同比增长约55%；产品收入同比增长约72.6%至约38亿美元。4月30日早间，百济神州公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics在‘803 专利授权后复审程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提起上诉。公司表示，百悦泽是其原研药品，公司将对此类专利侵权指控进行坚决的辩护。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1969619763.USD","06160","BK1500","LU2328871848.SGD","BK1583","BK1161","BK4139","LU0307460666.USD","ONC","BK1588","LU0588546209.SGD","688235"],"gpt_icon":0},{"id":"2531031201","title":"百济神州在美国专利纠纷中获胜，USPTO裁定相关专利无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031201","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531031201?lang=zh_cn&edition=full","pubTime":"2025-04-30 20:10","pubTimestamp":1746015004,"startTime":"0","endTime":"0","summary":"4月30日，百济神州公告表示，美国专利商标局近日作出决定，宣告Pharmacyclics公司持有的第11672803号美国专利全部权利要求无效。这一裁定源于百济神州及其美国子公司与Pharmacyclics之间的一场专利纠纷。面对指控，百济神州迅速作出反应，于2023年11月向USPTO提交专利授权后复审申请，对“803专利”的合法性提出质疑。同时，法院也暂缓了侵权诉讼的审理，以待USPTO的裁决结果。基于以上理由，USPTO最终裁定“803专利”全部权利要求无效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2531269085","title":"百济神州04月30日获主力加仓1889.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531269085","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531269085?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000951,"startTime":"0","endTime":"0","summary":"04月30日, 百济神州股价涨6.04%，报收158.00元，成交金额11.6亿元，换手率0.57%，振幅6.38%，量比1.20。百济神州今日主力资金净流入1889.6万元，上一交易日主力净流入1027.6万元。该股近5个交易日上涨4.29%，主力资金累计净流入2.1亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入4.3亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171356a46d7683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171356a46d7683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","LU0307460666.USD","06160","BK1588","BK1161","LU0588546209.SGD","LU1969619763.USD","BK1500","BK1583"],"gpt_icon":0},{"id":"2531056717","title":"百济神州：Pharmacyclics诉讼所涉专利被裁定无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531056717","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531056717?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:16","pubTimestamp":1745993763,"startTime":"0","endTime":"0","summary":"中新经纬4月30日电 30日早间，百济神州发布一则涉及诉讼的公告。该诉讼起源于2023年6月，美国生物制药公司艾伯维旗下的Pharmacyclics公司指控百济神州的药物泽布替尼侵犯专利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2531722937","title":"创新药产业链表现良好，百济神州、诺诚健华、恒瑞医药等持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722937","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531722937?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:14","pubTimestamp":1745993640,"startTime":"0","endTime":"0","summary":"创新药产业链表现强劲，多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%，核心产品泽布替尼和替雷利珠单抗收入显著增长，预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种，奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现，认为医药行业将迎来结构性机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","LU2328871848.SGD","LU2148510915.USD","BK0188","LU1064131003.USD","LU1064130708.USD","09969","BK0060","BK0012","ONC","688428","LU1969619763.USD","BK0183","06160","159992","600276","LU2488822045.USD","688235","LU0405327494.USD","BK0239","BK0196","LU0405327148.USD","LU1328615791.USD"],"gpt_icon":0},{"id":"2531708753","title":"百济神州“泽布替尼”专利侵权案胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708753","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531708753?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:59","pubTimestamp":1745992799,"startTime":"0","endTime":"0","summary":"4月30日，百济神州宣布，美国专利商标局（USPTO）作出了一项最终书面决定，宣布艾伯维旗下Pharmacyclics LLC在专利授权后复审（PGR）程序中受到百济神州质疑的第11672803号美国专利（‘803专利）的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提出上诉。该诉讼经过如下：2023年6月15日，Pharmacyclics指控百济神州BTK抑制剂百悦泽（泽布","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2531377644","title":"回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531377644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531377644?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:36","pubTimestamp":1745991360,"startTime":"0","endTime":"0","summary":"回港中概股午后走强，金山云涨超13%，百济神州涨超7%，万国数据涨超6%，宝尊电商、BOSS直聘涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30133650037219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1134","BK1583","BK1585","688235","BK4585","BK4220","LU1023057109.AUD","LU0359201612.USD","BK1607","BK4588","BK4122","BK4607","LU0348767384.USD","BK4503","LU1969619763.USD","09698","BK4077","BZ","BK4614","ONC","LU0588546209.SGD","LU1688375341.USD","BK1518","TTTN","BK1500","BK4505","BK4563","BK0239","LU0359202008.SGD","BK4509","BK1613","BK1517","BK1588","BK4608","BK1526","LU2039709279.SGD","BK4551","06160","BK4531","LU0307460666.USD","BK4502","BZUN","BK1575","LU0348766576.USD","BK1586","03888","GDS","BK1589"],"gpt_icon":0},{"id":"2531754057","title":"回港中概股午后走强，金山云(03896.HK)涨超13%，百济神州(06160.HK)涨超7%，万国数据(09698.H","url":"https://stock-news.laohu8.com/highlight/detail?id=2531754057","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531754057?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:33","pubTimestamp":1745991202,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"02ef7766aaeb258258a594519db630be","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03896","BK0239","BK1249","BK1517","BK4558","BK1500","LU2328871848.SGD","BK4503","BK4608","BK1607","BK4535","BK4551","LU0348767384.USD","ONC","BK1586","TTTN","BK4563","BZ","09991","BK4502","BK4505","BK4526","LU2039709279.SGD","03888","BK4614","BK1588","BK4509","688235","LU1023057109.AUD","BK4077","KC","BZUN","BK1142","06160","BK1501","BK1502","BK1531","LU0359201612.USD","BK1518","02076","BK4122","BK1526","GDS","BK4529","BK4607","BK1583","BK1589","09698","BK1585","BK4220"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531735757?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0209","688235","688382","159992","BK0132","LU0405327494.USD","BK1583","LU1328615791.USD","ONC","159982","BK0060","600276","06160","06978","BK1161","LU1969619763.USD","BK0196","LU1064130708.USD","BK1500","LU2488822045.USD","09969","688266","399300","BK0239","688428","BK0187","LU0405327148.USD","BK1574","BK0012","BK0028","LU0307460666.USD","LU2148510915.USD","LU2328871848.SGD","BK4139","BK0175","LU1064131003.USD","BK1588","LU0588546209.SGD","BK0183","BK0188","002422","000963"],"gpt_icon":0},{"id":"2531560727","title":"百济神州美股专利纠纷胜诉午盘涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531560727","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531560727?lang=zh_cn&edition=full","pubTime":"2025-04-30 12:07","pubTimestamp":1745986022,"startTime":"0","endTime":"0","summary":"4月30日，百济神州股价午盘涨5.50%，报157.20港元。美国专利商标局宣布Pharmacyclics的‘803专利全部权利无效，公司原研药百悦泽®未侵权。去年百济神州收入38.1亿美元，同比增长55%，产品收入增长72.6%。强劲业绩得益于百悦泽®的成功及丰富的肿瘤管线，预计2025年将有多个项目数据读出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":-0.0595},{"period":"3month","weight":0.1174},{"period":"6month","weight":0.2578},{"period":"1year","weight":0.5483},{"period":"ytd","weight":0.4029}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":-0.0082},{"period":"3month","weight":0.1003},{"period":"6month","weight":0.0816},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.1297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.050268},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.068807}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.3","shortVersion":"4.33.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}